Karyopharm Therapeutics Inc
NASDAQ:KPTI
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.7574
  • TODAY'S CHANGE (%)
    -0.0726 (-8.7470%)
  • Bid / Lots
    0.7412/ 10
  • Ask / Lots
    0.7650/ 50
  • Open / Previous Close
    0.8300 / 0.8300
  • Day Range
    0.7401
    0.8300
  • 52 Week Range
    0.6174
    1.9500
  • Volume
    1,217,739

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 7 hours ago by PR Newswire
      Companies Mentioned: KPTI

      Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 17,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of September 30, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

    • 7 hours ago by Dow Jones
      Companies Mentioned: KPTI

      Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      PR Newswire

      NEWTON, Mass., Oct. 1, 2024

      NEWTON, Mass., Oct. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 17,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of September 30, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Sep 3, 2024

Peers Headlines